Suzhou’s CStone Pharma has been approved to start an Australian Phase I clinical trial of its CDK4/6 inhibitor as a treatment for solid tumor cancers. CS3002 is a selective inhibitor of the cyclin-dependent kinases 4 and 6 (CDK4/6), a...
Read moreLuye Pharma of Yantai has been approved to start Japan trials of its novel treatment for depression, a serotonin-norepinephrine-dopamine triple reuptake inhibitor (SNDRI) in extended release tablet form. Ansofaxine Hydrochloride ER Tablets...
Read moreAmerican medical machinery firm Thermo Fisher Scientific has agreed to build a new factory in China’s Jiangsu province with a vision of long-term development in the country. The base, located in Suzhou High-Tech Zone, will make disposable...
Read morePfizer announced it is putting an additional $500 million into the construction of its gene therapy manufacturing site in Sanford, North Carolina. It is planned to support the company’s investment in gene therapy research and development, much...
Read moreYaoyanshe, a Shanghai on-line AI-based CRO/CMO, raised $42 million in a C funding round led by Eastern Bell Capital and Sequoia China. Founded in 2015, Yaoyanshe offers Trial.Link, a repository of China clinical trial information that connects...
Read moreAlligator Bioscience (Nasdaq Stockholm: ATORX), today announces that a license agreement has been reached with Biotheus Inc. (“Biotheus”), a privately held Chinese company based in Zhuhai, Guangdong, China. Under the license...
Read moreClick here to find more details This is NAI’s new China News Weekly. We will be covering the latest Chinese foreign investment trends every week. To continue to receive our China News Weekly, please click the button below to subscribe.
Read moreLHHC Medical Technology, a China AI company, announced a global cooperation with Vancouver’s Enlighta to market LHHC’s early cancer detection test. The “No Cancer” technology combines LHHC’s AI data models and...
Read moreChina has added 148 drugs to its list of medicines covered by basic medical insurance plans, the first update in two years. The additions were comprised of 47 western drugs and 101 TCM products, including medicines for cancers, rare diseases...
Read moreShenzhen Xpect Vision Technology closed a $14 million B financing to support development of its new imaging technologies. Founded in 2015, Xpect considers itself a leader in photon-counting X-ray imaging along with other new technologies such as...
Read moreShenzhen’s China Medical System acquired China rights to seven generic drugs from India’s Sun Pharma. The seven drugs were not identified, but Sun Pharma said they have China market revenues of $1 billion annually. Two months ago, CMS...
Read moreIndia’s Natco Pharma, a company that specializes in complex generics, plans to build up its business in China, taking advantage of China’s speeded-up approval process to register products that are already approved elsewhere. Natco has...
Read more
